Treatment

limitation
Significant impairment or deterioration in lung function
Significant changes on x-rays (cavities, fibrosis, conglomerates, pulmonary hypertension)
Damage to the heart, nervous system, or eyes
Renal or hepatic impairment
Moderate to severe hypercalcemia
Disfiguring lesions of the skin or joints
For the treatment of discomfort from the musculoskeletal system, NSAIDs are used.

scans without significant symptoms or evidence of decreased organ function is not an indication for treatment.
The standard protocol is prednisone 20–40 mg orally once a day, depending on symptoms and severity of the disease. Alternatively, you can use an every other day regimen: for example, prednisone 40 mg orally once every other day.
Although patients rarely need a dose> 40 mg / day, higher doses may be required to reduce complications of neurological disease. Response usually occurs within 6-12 weeks, so symptoms and pulmonary function tests can be re-evaluated between 6 and 12 weeks. In chronic and latent cases, the reaction may be delayed. If there is an effect, the dose of corticosteroids is gradually reduced to maintenance (for example, prednisone 10-15 mg / day); with improvement, therapy is continued for at least 6-12 months.

may lead to relapse. In case of a doubtful reaction or ineffectiveness of treatment, the use of the drug is gradually discontinued. Ultimately, corticosteroids can be discontinued in most patients, but since relapse occurs in 50% of cases, follow-up examinations should be performed, usually every 3–6 months.
Treatment with corticosteroids should be resumed if complaints and symptoms recur, including dyspnea, arthralgia, fever, liver failure, cardiac arrhythmias, CNS symptoms, hypercalcemia, eye damage, lack of topical drug control, and disfiguring skin lesions. Because low doses of corticosteroids suppress ACE production, it may be useful to monitor serum ACE levels over time when assessing adherence to corticosteroid treatment in the presence of elevated ACE levels.

airway hyperresponsiveness. Inhalation of large doses of budesonide or fluticasone has sometimes been shown to be effective in pulmonary stages I-III, while combinations of systemic and inhaled steroids have a positive effect on both clinical symptoms and changes on radiographs in stages II-IV.
Local corticosteroids may be helpful in treating dermatitis, sinusitis, and eye diseases.
When treating with corticosteroids or immunosuppressants, prophylaxis for Pneumocystis jirovecii pneumonia should be considered.

to moderate doses of corticosteroids, refractoriness of sarcoidosis to corticosteroids, or if treatment with corticosteroids is required for a long time.
In about 10% of cases when therapy is necessary, tolerated doses of corticosteroids are ineffective, and a 6-month trial of methotrexate therapy at a dose of 10-15 mg / week should be carried out. Methotrexate and corticosteroids are given initially; after 6-8 weeks, the dose of corticosteroids can be gradually reduced, and in many cases their use can be discontinued. However, the maximum effect of methotrexate can be observed after 6-12 months. In such cases, the dose of prednisolone should be decreased more slowly. Determination of blood corpuscles and liver enzymes should be performed first every 1–2 weeks, then every 4–6 weeks, as soon as a stable dose is reached. In patients receiving methotrexate, folate (1 mg orally per day) is recommended.